What is Aetion?
Aetion operates at the intersection of healthcare and technology, providing the Aetion Evidence Platform. This sophisticated platform is designed to analyze real-world data, delivering transparent, rapid, and scientifically validated insights into treatment efficacy, associated costs, and patient outcomes. Leveraging decades of expertise in epidemiology and health outcomes research, Aetion empowers life sciences companies to make informed decisions regarding treatment development, commercialization strategies, and payment innovations. The company's focus on generating robust real-world evidence positions it as a critical partner for organizations navigating the complexities of modern healthcare.
How much funding has Aetion raised?
Aetion has raised a total of $203.2M across 3 funding rounds:
Series A
$11.2M
Series B
$82M
Series C
$110M
Series A (2017): $11.2M with participation from Flare Capital Partners and Lakestar
Series B (2020): $82M led by EDBI, Flare Capital Partners, Oxeon, JJDC, Lakestar, Greenspring Associates, and Amgen Business Development
Series C (2021): $110M supported by New Enterprise Associates, Flare Capital Partners, B Capital Group, Foresite Capital, and Warburg Pincus
Key Investors in Aetion
Flare Capital Partners
Flare Capital Partners is a leading investor focused on healthcare technology, collaborating with entrepreneurs to enhance healthcare outcomes and reduce costs. The firm supports a diverse portfolio of companies addressing critical challenges within the healthcare industry.
Lakestar
Lakestar is a venture capital firm dedicated to partnering with visionary tech entrepreneurs to fund innovative ideas and companies that shape modern life. They focus on sectors such as Deep Tech, Healthcare, Fintech, and Digitalisation, investing with a long-term perspective from Seed to Growth stages.
EDBI
EDBI is a global investor based in Singapore, focusing on high-growth technology sectors since 1991. The company aims to create value and empower businesses to build sustainable legacies through strategic investments.
What's next for Aetion?
With its substantial funding, Aetion is poised for continued expansion and innovation in the real-world evidence space. The company's Series C financing, which was undisclosed, suggests a significant scaling phase, likely enabling further development of its platform, expansion into new markets, and strengthening of its data analytics capabilities. Aetion's strategic investments will likely focus on enhancing its ability to provide actionable insights to pharmaceutical companies, payers, and providers, thereby influencing critical healthcare decisions and driving advancements in patient care. The company's trajectory indicates a strong commitment to becoming a leader in evidence-based healthcare solutions.
See full Aetion company page
